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OBJECTIVE—Cerebral edema is a life-threatening complica-
tion of diabetic ketoacidosis (DKA) in children. Recent data
suggest that cerebral hypoperfusion and activation of cerebral
ion transporters may be involved, but data describing cerebral
metabolic alterations during DKA are lacking.
RESEARCH DESIGN AND METHODS—We evaluated 50 ju-
venile rats with DKA and 21 normal control rats using proton and
phosphorus magnetic resonance spectroscopy (MRS). MRS mea-
sured cerebral intracellular pH and ratios of metabolites includ-
ing ATP/inorganic phosphate (Pi), phosphocreatine (PCr)/Pi,
N-acetyl aspartate (NAA)/creatine (Cr), and lactate/Cr before and
during DKA treatment. We determined the effects of treatment
with insulin and intravenous saline with or without bumetanide,
an inhibitor of Na-K-2Cl cotransport, using ANCOVA with a 2 
2 factorial study design.
RESULTS—Cerebral intracellular pH was decreased during
DKA compared with control (mean  SE difference 0.13 
0.03; P  0.001), and lactate/Cr was elevated (0.09  0.02; P 
0.001). DKA rats had lower ATP/Pi and NAA/Cr (0.32  0.10,
P  0.003, and 0.14  0.04, P  0.001, respectively) compared
with controls, but PCr/Pi was not signiﬁcantly decreased. During
2-h treatment with insulin/saline, ATP/Pi, PCr/Pi, and NAA/Cr
declined signiﬁcantly despite an increase in intracellular pH.
Bumetanide treatment increased ATP/Pi and PCr/Pi and amelio-
rated the declines in these values with insulin/saline treatment.
CONCLUSIONS—These data demonstrate that cerebral metab-
olism is signiﬁcantly compromised during DKA and that further
deterioration occurs during early DKA treatment—consistent
with possible effects of cerebral hypoperfusion and reperfusion
injury. Treatment with bumetanide may help diminish the ad-
verse effects of initial treatment with insulin/saline. Diabetes
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erebral injury resulting from diabetic ketoacido-
sis (DKA) is the most frequent diabetes-related
cause of death in children. The cause of this
complication has been a subject of much debate
and is not well understood. Recent data from studies using
an animal model demonstrate that DKA is associated with
reduced cerebral blood ﬂow and with brain cell swelling
(1,2). The same studies suggest that activation of cerebral
microvascular endothelial ion transport (particularly Na-
K-Cl cotransport) during DKA contributes to brain cell
swelling in this setting, as it does in animal models of
stroke. During DKA treatment with insulin and intrave-
nous ﬂuids, cerebral blood ﬂow rises and vasogenic edema
develops (3,4). These data suggest that cerebral injury
resulting from DKA may be similar to hypoxic/ischemic
brain injury resulting from stroke or other causes and raise
the question of whether bumetanide, an inhibitor of Na-
K-Cl cotransport, may be helpful in reducing cerebral
injury in the setting of DKA.
Children who develop DKA-related cerebral injury often
present with normal mental status or only mild mental
status abnormalities. After several hours of DKA treat-
ment, however, these patients have a decline in mental
status often followed by loss of consciousness and some-
times by clinical signs of increased intracranial pressure.
Although a small percentage of children have clinically
apparent cerebral injury at presentation of DKA prior to
treatment, neurological decline during DKA treatment is
more common (5–7). Why children may worsen during
treatment with insulin and intravenous ﬂuids is not clear.
Initial hypotheses focused on the role of ﬂuid infusion and
osmotic change in brain cell swelling (8,9). More recent
data suggest instead that reperfusion injury or related
mechanisms may be more likely (1–3).
Magnetic resonance spectroscopy (MRS) provides a
noninvasive method for evaluating cerebral metabolism.
Proton MRS can be used to measure concentrations of
lactate in the brain, as well as the relative concentrations
of N-acetyl aspartate (NAA) and creatine (Cr), a measure
thought to be indicative of neuronal health (10,11). In
stroke and other forms of hypoxic/ischemic brain injury,
brain lactate is elevated and NAA/Cr is reduced. Phospho-
rus MRS can be used to measure cerebral intracellular pH
and concentrations of high-energy phosphates, which typ-
ically decrease during hypoxia/ischemia (12–15).
MRS provides an ideal method to evaluate the cerebral
metabolic alterations associated with DKA and the
changes in cerebral metabolic state that occur during DKA
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took the current study to characterize these metabolic
changes and to determine the effects of treatment with
bumetanide, an inhibitor of Na-K-2Cl cotransport in the
blood-brain barrier (BBB) and astrocytes, as well as many
other cell types, on these metabolic alterations. In analogy
with ischemia/reperfusion injury, we hypothesized that
DKA would be associated with metabolic abnormalities
similar to those of hypoxic/ischemic brain injury and that
these abnormalities would worsen during initial DKA
treatment as normal cerebral perfusion is reestablished.
Further, we hypothesized that bumetanide treatment
would result in improvements in the cerebral metabolic
state.
RESEARCH DESIGN AND METHODS
A sequence of two experiments was performed. The ﬁrst experiment com-
pared metabolic measures in 50 rats with DKA to 21 normal control rats. DKA
rats were then randomized to one of the four treatment combinations from a
2  2 factorial experiment designed to assess the treatment effects of
insulin/saline and bumetanide. Twelve rats were treated with bumetanide
only, 11 with insulin/saline only, 14 with both and 13 DKA control rats were
treated with neither. To assess whether estimates of the bumetanide-only
effect could be confounded with the small volume of saline ﬂuid used to
deliver bumetanide intravenously, ﬁve of the 13 DKA control rats were
intentionally treated with a small volume of saline and compared with the
remaining control rats.
Induction of DKA. Seventy-one 4-week-old Sprague-Dawley rats (150 g;
Charles River Laboratories, Wilmington, MA) were given an intraperitoneal
injection of streptozotocin (STZ) (150 mg/kg; n  50) or STZ vehicle as
previously described (1). Rats were given unlimited access to D10W (water
with 10% dextrose; Fisher Scientiﬁc, Santa Clara, CA) in the ﬁrst 24-h period
after STZ injection to prevent hypoglycemia and then were subsequently
allowed unlimited access to tap water and standard rat chow. Rats were
weighed daily. Urine glucose and ketoacids (acetoacetate) were measured
using Multistix urinalysis strips (Fisher Scientiﬁc; Bayer) as previously
described (1). Rats in the DKA group had urine glucose and acetoacetate
concentrations 110 mmol/l and 15,680 mol/l, respectively. To induce a
level of dehydration similar to severe human DKA and to ensure acidosis, we
deprived rats of drinking water 24 h before imaging. This study was conducted
in accordance with the Animal Use and Care Guidelines issued by the National
Institutes of Health using a protocol approved by the Animal Use and Care
Committee at the University of California, Davis.
Magnetic resonance imaging. MRS measurements were performed in
anesthetized rats in a horizontal bore magnet (Oxford Instruments, Oxford,
U.K.) using a two-channel Biospec system (Bruker Biospin, Billerica, MA)
running ParaVision software. A double-tuned 1H/X Litz coil (Doty Scientiﬁc,
Columbia, SC) was used, where X is tunable for
23Na or
31P. Field homoge-
neity was optimized by localized shimming on
1Ho v e ra9 9  9 mm voxel
of interest (VOI). The VOI was positioned inside the brain and selected to
encompass as much of the cortex as possible. After shimming,
31P- and
1H-MRS data were acquired.
31P-MRS. An 8  8  8 mm VOI was centered on the shimmed volume.
Spectra were acquired in 43.2-min intervals using Bruker software for
image-selected in vivo spectroscopy, (repetition time [TR] 4 s, 80 signals
averaged, and 26-Hz line broadening). Intracellular pH was calculated from
the chemical shift of the inorganic phosphate (Pi) peak relative to the
phosphocreatine (PCr) peak using the equation pHi  6.7  log [(shift 
3.186)/(5.691  shift)] (16). PCr, -ATP, and Pi peaks were integrated using
NUTS software (Acorn NMR, Livermore, CA) and presented as ratios (ATP to
Pi and PCr to Pi).
1H-MRS. A7 7  7 mm VOI was centered on the shimmed volume.
Acquisition of
1H-MRS data was initiated immediately after
31P-MRS acquisi-
tion was completed. Spectra were collected in 2.8-min intervals, but to
improve the signal-to-noise ratio for
1H measurements, two 2.8-min ﬁles were
added together for ﬁnal analysis. Data were acquired using Bruker software
for point-resolved spectroscopy (TR 6,974 ms, 20 signals averaged, and 2-Hz
line broadening) with chemical shift–selective pulses and dephasing gradients
to suppress water. Cerebral
1H metabolite peaks were identiﬁed according to
their chemical shifts (17): NAA 2.02 ppm, Cr 3.0 ppm, lactate 1.38 ppm, and
-hydroxy butyrate (OHB) 1.15 ppm. With an echo time (TE) of 132 ms, the
lipid peak was suppressed, and the lactate and OHB appeared as inverted
peaks. The NAA, Cr, lactate, and OHB peaks were integrated using NUTS
software and presented as ratios (NAA to Cr, lactate to Cr, and OHB to Cr).
Experimental treatments: saline and insulin infusion. For treatment with
saline and insulin, rats were infused via cannulated femoral vein with regular
insulin at 1.5 units  kg
1  h
1 (Humulin; Lilly & Company, Indianapolis, IN)
and 0.9% NaCl at 80 ml  kg
1  h
1 for 1 h, followed by infusion with insulin
and saline at 1.5 units  kg
1  h
1 and 40 ml  kg
1  h
1, respectively, for the
remainder of the 2-h experiment. These rates were determined by compari-
sons of human versus rat metabolic rate, body surface area, and percentage
dehydration during DKA. In initial studies, these rates of infusion resulted in
biochemical changes during DKA treatment (decline in serum glucose and
urea nitrogen concentrations and resolution of acidosis) at rates similar to
those observed in children with DKA.
Bumetanide treatments. For experiments designed to evaluate the effects of
bumetanide on cerebral metabolite concentrations, bumetanide (30 mg/kg)
was administered in one of two ways. For rats not receiving intravenous
infusion of saline and insulin, bumetanide was injected into a femoral vein
cannula (0.8 cc total volume) immediately before the start of imaging, as
previously described (1). For rats treated with saline and insulin infusion,
bumetanide was given via femoral vein cannula at the start of the saline and
insulin infusion. Bumetanide (ICN Biomedicals, Costa Mesa, CA) was pre-
pared as previously described (1).
Animal preparation for imaging. Prior to imaging, rats were anesthetized
using Na pentobarbital (65 mg/kg i.p.). Body temperature was monitored via
rectal probe (Cole-Parmer Instruments, Vernon Hills, IL), and a heating pad
with circulating water (Gaymar Inc., Orchard Park, NY) maintained body
temperature at 36.8–37.0°C throughout surgery and brain imaging. The
femoral artery and vein were cannulated for blood sampling and for drug and
treatment infusion, respectively. Rats were subjected to tracheal intubation
and ventilated (Harvard Small Animal Ventilator, Holliston, MA) throughout
surgery and imaging. Ventilation was done to offset the tendency toward
respiratory depression in the anesthetized rats and thereby ensure that the animal
model closely mimicked human DKA. Blood samples were analyzed for pCO2 and
pH immediately after intubation and the respiratory rate and tidal volume
adjusted with the goal of maintaining pCO2 levels within the range expected for
a normal physiological response to the degree of acidosis (18).
Blood chemistry. Blood samples were withdrawn from the femoral artery
cannula, before and hourly during imaging, and from the abdominal aorta, after
imaging, at the conclusion of the experiment. We measured serum electrolyte
concentrations, pH, blood urea nitrogen, and glucose concentrations using an
I-STAT portable clinical analyzer (Sensor Devices, Waukesha, WI).
Statistical analysis. All statistical analyses were conducted using version 9.1
of the SAS system for Windows. Two-sided testing was used for all study
hypotheses, with P values 0.05 considered statistically signiﬁcant and
between 0.05 and 0.10 considered representative of a trend.
Statistical analysis began with graphical and numerical summaries of the
distributions of study outcomes and baseline measurements. When indicated,
variables were log transformed to ameliorate skewness or to stabilize vari-
ances across the groups under comparison. Group-speciﬁc (geometric) means
and (geometric) SDs are reported for (log-transformed) baseline measures. At
baseline, biochemical measures for some rats fell above or below the
detection limits of measurement (blood urea nitrogen, log-transformed TCO2,
and serum glucose concentrations). To account for this, maximum likelihood
estimates of pretreatment distribution parameters for these measures were
produced, with normal distributions assumed.
For comparing DKA rats with normal control rats, Student’s independent-
groups t test was used for all outcomes except those with some values outside
the detection limits of measurement, which were analyzed using maximum-
likelihood estimates of regression models for heterogeneous, limited, depen-
dent, and normally distributed variables (using SAS PROC QLIM). These
models used a single independent variable that indicated group membership
(one “DKA rat” versus zero “control rat”). The coefﬁcient for this regressor
was compared with the heterogeneity-robust SE estimate to form the t
statistic used for testing between-group differences.
Student’s t test was used within the set of DKA control rats to compare the
eight untreated rats with the ﬁve administered a small amount of saline. These
comparisons were performed on baseline values and on change scores (from
pre- to posttreatment). After establishing that these two subgroups did not
have statistically signiﬁcant differences on any comparison, the two sub-
groups were analyzed as a single group in subsequent analyses.
Within each of the four factorial treatment combinations, over-time
changes in metabolite ratios were assessed using paired t tests comparing pre-
and posttreatment values. Between-group comparisons on over-time changes
were conducted using ANCOVA models for a 2  2 factorial experiment, with
main effects for the two binary treatment factors and, when indicated,
heterogeneous error variance components. Baseline covariates were selected
based on a preliminary stage of analysis that aimed to ﬁnd a parsimonious set
of predictors to improve model ﬁt and the precision of estimates of main
treatment effects. This set included serum pH for all study outcomes and, for
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value of TCO2 was outside the limit of detection. PCO2 was also evaluated as
a candidate variable for inclusion in the model but was not found to improve
model ﬁt. Between-model comparisons for goodness of ﬁt were performed
using the Akaike information criterion and by comparing the root mean square
error of the residuals. Analysis of residuals and inﬂuence statistics and ﬁts of
alternative regression models (with interaction terms) were used to verify that
models for mean and covariance parameters were appropriately speciﬁed,
were not unduly inﬂuenced by a small number of extreme observations, and
satisﬁed distributional assumptions needed for valid hypothesis testing. To
accommodate the features of our ﬁnal model, we used PROC MIXED to
estimate model parameters using restricted maximum-likelihood estimates for
variance components.
RESULTS
Biochemical values for DKA and normal control rats are
summarized in Table 1. Using phosphorus MRS, we found
that rats with DKA had signiﬁcantly decreased cerebral
intracellular pH compared with that in normal control rats
(Fig. 1). Peaks corresponding to the ketone body, OHB,
were readily detectable on proton MRS in DKA rats (mean
OHB-to-Cr ratio 0.16  0.12), whereas no such peaks
could be identiﬁed in normal control rats. Lactate-to-Cr ratios
were signiﬁcantly increased on proton MRS in DKA rats, and
NAA-to-Cr ratios were signiﬁcantly decreased compared
with control values. In phosphorus MRS, ATP-to-Pi ratios
were signiﬁcantly decreased in DKA rats compared with
those in normal controls, but PCr-to-Pi ratios were not
signiﬁcantly different between the two groups.
When rats with DKA were treated with intravenous
insulin and saline, a deterioration in MRS measures of
cerebral metabolism occurred (Figs. 2 and 3). We ob-
served a signiﬁcant decrease in ATP-to-Pi, PCr-to-Pi, and
NAA-to-Cr ratios in rats treated with insulin and saline for
2 h (Fig. 4A–C). These changes occurred despite improve-
ments in cerebral intracellular pH (Fig. 4D) and decreased
brain levels of OHB (cerebral OHB-to-Cr 0.12  0.07
before treatment vs. 0.03  0.03 after treatment; P 
0.001), consistent with improvements in the ketoacidotic
state. In contrast, rats with DKA who were left untreated
for the same 2-h period had no signiﬁcant changes in
ATP-to-Pi, PCr-to-Pi, and NAA-to-Cr ratios, cerebral intra-
TABLE 1
Biochemical values in normal control rats and in rats with DKA
before and after 2-h treatment with insulin and saline infusion
Control
DKA before
infusion
DKA after
2-h saline and
insulin infusion
n 21 49 11
Glucose (mmol/l) 7.9  0.9 35.7  9.1 17.3  8.4
BUN (mmol/l 3.9  1.1 34.3  13.2 25.3  10.7
pH 7.42  0.06 7.10  0.23 7.20  0.13
Total CO2 (mmol/l 27  17  21 2  1
Data are means  SD for glucose, BUN, and pH and geometric
means  SD for total CO2. DKA preinfusion values represent pooled
values for all DKA treatment groups. Postinfusion values include rats
in the standard (insulin and saline) DKA treatment group only.
Among DKA rats before infusion, 20 of 49 had glucose measurements
above the detection limit of 38.5 mmol/l, 9 of 49 had BUN measure-
ments above the detection limit of 50 mmol/l, and 18 of 48 had a total
CO2 measurement below the detection limit of 5 mmol/l. Pretreat-
ment parameters for BUN, glucose, and total CO2 are maximum-
likelihood estimates, as described in RESEARCH DESIGN AND METHODS.
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FIG. 1. Cerebral metabolites measured by
1H- and
31P-MRS in DKA and control rats. A: ATP-to-Pi ratios. B: PCr-to-Pi ratios. C: NAA-to-Cr ratios.
D: Intracellular pH. E: Lactate-to-Cr ratios. All values are means (95% CI). A and B are geometric means; C, D, and E are arithmetic means. n 
20 for control and 41 for DKA rats in C and D; n  20 for control and 44 for DKA rats in A, B, and E. *Values are signiﬁcantly different from those
of the control group; P values <0.005.
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(0.17  0.06 vs. 0.18  0.11; P  0.84).
When bumetanide was added to the insulin and saline
treatment, the mean ATP-to-Pi, PCr-to-Pi, and NAA-to-Cr
ratios showed no signiﬁcant change during treatment
rather than declining (Fig. 4A–C). Treatment of DKA rats
with bumetanide alone, without insulin or saline, resulted
in improvements in some metabolic measures. ATP-to-Pi
ratio rose signiﬁcantly, and there was a trend toward an
increase in PCr-to-Pi ratio (P  0.051). NAA-to-Cr levels,
however, did not improve signiﬁcantly in this group, and
intracellular pH did not either (Fig. 4D). Results of the
ANCOVA analysis (Table 2) conﬁrmed signiﬁcant oppos-
ing effects of insulin and saline versus bumetanide. While
insulin and saline treatment worsened MRS metabolic
measures despite improvements in intracellular pH, bu-
metanide treatment tended to improve MRS metabolic
measures without signiﬁcantly changing intracellular pH.
DISCUSSION
Case reports of cerebral edema and cerebral injury occur-
ring during DKA in children often describe the child’s
initial mental state as normal or nearly normal at the time
Cr NAA
0Hr
Lact
2Hr
PPM 1.5 2.0 2.5 3.0 3.5
βOHB
FIG. 2.
1H-MR spectra obtained before DKA treatment and at the end of 2-h treatment with insulin and saline. Lact, lactate.
PPM -10 -15 0- 5 5
PCr
Pi
0Hr
2Hr
β-ATP
α− γ−
FIG. 3.
31P-MR spectra obtained before DKA treatment and at the end of 2-h treatment with insulin and saline. , ATP; , ATP.
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with insulin and intravenous ﬂuids, however, a decline in
mental status occurs, often with loss of consciousness,
seizures, or other substantial neurological abnormalities
(19–21). This decline in mental status occurs despite
improvements in acidosis and hyperglycemia. Although
clinically apparent cerebral edema and cerebral injury can
also occur before treatment of DKA, the more frequent
occurrence of cerebral edema during DKA treatment sug-
gests that some aspect of treatment may cause or enhance
cerebral injury.
Our data demonstrate that cerebral intracellular pH is
low during untreated DKA, cerebral lactate levels are high,
and levels of high-energy phosphates are low, similar to
cerebral ischemia. NAA-to-Cr ratios are also decreased,
suggesting neuronal compromise or injury (10–14,22–25).
Taken together with our previous results demonstrating
that DKA diminishes cerebral blood ﬂow in this model (2),
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FIG. 4. A: ATP-to-Pi ratios in DKA rats before and after saline and insulin infusion with and without bumetanide. ATP-to-Pi ratios were measured
by
31P-MRS as described in RESEARCH DESIGN AND METHODS. Bumetanide alone and saline plus insulin with and without bumetanide treatments were
started immediately after baseline measurements (0 h). All values are geometric means (95% CI); n  12, 10, 10, and 12 for no treatment,
bumetanide alone, saline and insulin, and saline and insulin with bumetanide treatment groups, respectively. *Within-group comparisons: P <
0.02 for comparison of pre-/posttreatment values in the bumetanide-alone group and the insulin-and-ﬂuid group. Refer to Table 2 for the overall
effects of insulin plus saline and bumetanide. Data were analyzed with log-transformed values. B: PCr-to-Pi ratios in DKA rats before and after
saline and insulin infusion with and without bumetanide. PCr-to-Pi ratios were measured by
31P-MRS as described in RESEARCH DESIGN AND METHODS.
Bumetanide alone and saline and insulin with and without bumetanide treatments were started immediately after baseline measurements (0 h).
All values are geometric means (95% CI); n  12, 10, 10, and 12 for no treatment, bumetanide alone, saline and insulin, and saline and insulin
with bumetanide treatment groups, respectively. *Within-group comparisons: P  0.01 for comparison of pre- and posttreatment values in the
insulin-and-ﬂuid group. P  0.051 for comparison of pre- and posttreatment values in the bumetanide-alone group. Refer to Table 2 for the overall
effects of insulin plus saline and bumetanide. Data were analyzed with log-transformed values. C: NAA-to-Cr ratios in DKA rats before and after
saline and insulin infusion with and without bumetanide. NAA-to-Cr ratios were measured by
1H-MRS as described in RESEARCH DESIGN AND METHODS.
Bumetanide alone and saline and insulin with and without bumetanide treatments started immediately after baseline measurements (0 h). All
values are arithmetic means (95% CI); n  13, 9, 9, and 10 for no treatment, bumetanide alone, saline and insulin, and saline and insulin with
bumetanide treatment groups, respectively. *Within-group comparisons: P  0.03 for comparison of pre- and posttreatment values in the
insulin-and-ﬂuid group. Refer to Table 2 for the overall effects of insulin plus saline and bumetanide. D: Intracellular pH in DKA rats before and
after saline and insulin infusion with and without bumetanide. Intracellular pH values were determined by
31P-MRS as described in RESEARCH
DESIGN AND METHODS. Bumetanide alone and saline and insulin with and without bumetanide treatments were started immediately after baseline
measurements (0 h). All values are arithmetic means (95% CI); n  12, 10, 10, and 12 for no treatment, bumetanide alone, saline and insulin, and
saline and insulin with bumetanide treatment groups, respectively. *Within-group comparisons: P < 0.05 for comparison of pre- and
posttreatment values in the insulin-and-ﬂuid group and the insulin-and-ﬂuid plus bumetanide group. Refer to Table 2 for the overall effects of
insulin plus saline and bumetanide.
MRS ASSESSMENT OF CEREBRAL METABOLISM IN DKA RATS
706 DIABETES, VOL. 59, MARCH 2010 diabetes.diabetesjournals.orgthese data provide further evidence consistent with the
hypothesis that cerebral hypoperfusion occurs in un-
treated DKA and may lead to cerebral injury. Similar
ﬁndings have been observed in both human and animal
studies of stroke and other ischemic brain injury, includ-
ing declines in brain concentrations of high-energy
phosphates, elevated brain lactate concentrations, and
decreased NAA-to-Cr ratios (12,14,15,23–26). Additionally,
our data provide the ﬁrst evidence that during initial DKA
treatment with insulin and intravenous saline, key aspects
of the cerebral metabolic state worsen. High-energy phos-
phate levels decline further, as does the NAA/Cr ratio.
These data suggest that the initial period of DKA treatment
may lead to additional cerebral injury possibly caused by
reperfusion of previously hypoperfused cerebral tissues or
some other aspect of treatment.
Data from previous studies suggest that hyperglycemia
augments ischemic brain injury (27–31). Hyperglycemia
results in increased brain lactate concentrations and re-
duced high-energy phosphate concentrations following an
ischemic insult (27,32). During ischemia and reperfusion,
hyperglycemia is associated with greater and more pro-
longed intracellular acidosis (28). Our data correlate well
with these ﬁndings and suggest that hyperglycemia may
result in greater vulnerability of the brain to injury result-
ing from diminished perfusion.
Although osmotic ﬂuctuations during DKA therapy have
been suspected to cause cerebral edema, our data are
more consistent with the effects of ischemia and reperfu-
sion. Limited data from other studies suggest that osmotic
ﬂuctuations do not result in changes in cerebral high-
energy phosphate levels (33). In addition, previous studies
by our group have demonstrated high apparent diffusion
coefﬁcient (ADC) values measured by magnetic resonance
diffusion weighted imaging during DKA treatment in chil-
dren (3) in contrast to the low ADC values observed in
cerebral edema induced by osmotic ﬂuctuations (34–36).
These data suggest that declines in osmolality during DKA
treatment are unlikely to be the main cause of cerebral
injury.
Although clinically apparent cerebral edema develops in
only 0.5–1% of DKA episodes in children, recent data
suggest that these children may represent only the most
severe presentation in a continuum of cerebral injury
caused by DKA (4,37). Data from magnetic resonance
studies of children undergoing DKA treatment suggest that
	50% have measurable cerebral edema (narrowing of the
cerebral ventricles) even in the absence of obvious neuro-
logical abnormalities (37). Furthermore, recent studies
suggest that even apparently uncomplicated DKA may be
associated with subtle but permanent neurocognitive def-
icits in children (38). These data suggest that DKA may
cause subtle cerebral injury in many children. Data from
the current study suggest that DKA is associated with
apparently adverse cerebral metabolic conditions and that
these conditions worsen during initial DKA treatment.
Whether severe, clinically apparent cerebral edema that
develops in a minority of children represents the most
extreme manifestation of these metabolic abnormalities or
whether additional cerebral insults or metabolic perturba-
tions are necessary to cause clinically apparent cerebral
edema is not yet clear. Additional studies will be necessary
to resolve this question.
In the current study, treatment with bumetanide, an
inhibitor of Na-K-2Cl cotransport, resulted in improve-
ments in metabolic measures during untreated DKA and
amelioration of the declines in metabolic measures during
initial DKA treatment. These data suggest a protective
effect of bumetanide. Previous data from our group have
demonstrated that untreated DKA is associated with re-
duced brain ADC values, suggesting brain cell swelling (1).
Bumetanide treatment in these studies resulted in an
increase in ADC, suggesting reduced cell swelling. While
elucidating the mechanisms underlying this effect of bu-
metanide will require further investigation, previous stud-
ies of the Na-K-Cl cotransporter in healthy and diseased
brain provide some clues. The Na-K-Cl cotransporter is
known to be present in cerebral microvascular endothelial
cells (the BBB), astrocytes, and neurons and to serve a
number of functions depending on cell type and prevailing
physiological and pathophysiological conditions. These
ﬁndings have previously been reviewed (39–44). Brieﬂy, in
healthy brain, the BBB Na-K-Cl cotransporter (predomi-
nantly in the luminal membrane) is thought to participate
in secretion of Na, Cl, and water from blood into brain,
accounting for up to 30% of brain interstitial ﬂuid genera-
tion. During the early hours of ischemic stroke, factors
including hypoxia, aglycemia, and vasopressin stimulate
activity of the BBB cotransporter, leading to increased
secretion of Na, Cl, and water across the intact barrier
from blood into brain (42,43,45). Ischemic factors also
stimulate astrocyte Na-K-Cl cotransport activity, causing
the cells to take up ions and water crossing the BBB and
to swell (cytotoxic edema). As ischemia progresses, the
endothelial cells themselves begin to swell by a process
that is at least partially dependent on Na-K-Cl cotrans-
porter activity. Ischemic stimulation of the cotransporter
can also cause swelling of neurons, although there is some
debate about the extent of neuronal swelling compared
with astrocytes. In addition, increased Na-K-Cl cotrans-
porter activity in GABAergic neurons causes elevation of
intracellular [Cl] and thus increased efﬂux of Cl through
GABA-activated Cl channels and depolarization of the
cells. Neuronal cotransporter activity is high in immature
neurons and appears to contribute to neonatal seizures
(41,46,47). In mature brain, the cotransporter may also
contribute to seizures occurring after ischemia and reper-
fusion by increasing intracellular [Cl] and causing hyper-
excitability of GABAergic neurons. Previous studies have
also shown that elevation of intracellular [Na] stimulates
Na/K ATPase activity, consequently increasing ATP
consumption as long as ATP is available (48,49); thus,
inhibition of Na uptake pathways can decrease ATP con-
sumption (50–53). The observed effects of bumetanide on
metabolic parameters in the present study are consistent
with the possibilities that 1) DKA-induced cerebral hyp-
oxia and ischemia stimulates Na-K-Cl cotransporter–medi-
TABLE 2
Individual effects of insulin and saline with bumetanide on
cerebral metabolites during DKA: regression-adjusted main ef-
fects of each treatment
Metabolite
Adjusted main
effect of insulin
and saline P
Adjusted main
effect of
bumetanide P
ATP-to-Pi 0.34  0.13 0.02 0.38  0.15 0.01
PCR-to-Pi 0.29  0.10 0.007 0.31  0.13 0.03
NAA-to-Cr 0.08  0.03 0.020 0.001  0.03 0.97
Intracellular pH 0.13  0.04 0.005 0.002  0.04 0.72
Data are means  SE unless otherwise indicated. ATP-to-Pi and
PCR-to-Pi ratios were analyzed as log-transformed values.
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elevating intracellular [Na] and stimulating Na/K ATPase
activity and ATP consumption, and that 2) bumetanide
reduces ATP consumption by reducing cotransporter-
mediated Na inﬂux.
Interestingly, although ATP-to-Pi ratio levels were sig-
niﬁcantly reduced in DKA rats, PCr-to-Pi levels in DKA rats
were not signiﬁcantly different from control values. These
data initially appear counterintuitive because declines in
PCr-to-Pi ratios caused by cerebral ischemia typically are
of greater magnitude than observed declines in ATP-to-Pi
ratios (13,14,23,54). Data from human studies of hypergly-
cemia, however, demonstrate that brain PCr concentra-
tions increase during hyperglycemia (55). A modest
increase in ATP concentrations also occurs, but the in-
crease in PCr is greater, resulting in an increase in the
PCr-to-ATP ratio. The lack of a detectable difference
between DKA rats and controls in PCr-to-Pi ratio in the
current study may therefore reﬂect higher baseline PCr
levels in the DKA rats induced by hyperglycemia.
The current study has some limitations. First, under
conditions where brain high-energy phosphate metabolism
is near normal, Pi levels are commonly near the noise level
obtained in our data. This is likely to have caused a relative
increase in variability for parameters dependent on Pi
(intracellular pH, PCr-to-Pi ratio, and ATP-to-Pi ratio),
particularly under control conditions. This variability may
have decreased our ability to detect differences of smaller
magnitude between groups. In addition, because of the
inherent limitations of mechanical ventilation in small
animals, we were not always able to precisely adjust the
animals’ pCO2 level to that expected for the degree of
acidosis. For these reasons, we conducted a subanalysis
including the pCO2 level as a covariate in the model.
Inclusion of pCO2 was not found to improve model ﬁt,
suggesting that differences in pCO2 level between the
groups did not have a signiﬁcant effect on the study
outcomes. Finally, although our data suggest a beneﬁcial
effect of bumetanide, we investigated only the initial phase
of DKA treatment. Whether bumetanide treatment results
in decreased neurological injury later in the course of DKA
treatment or improved outcomes after recovery from DKA
is not yet known.
In summary, our data demonstrate that DKA results in
metabolic changes in the brain similar to those occurring
in hypoxic and ischemic conditions. Furthermore, initial
DKA treatment with insulin and intravenous saline, rather
than resulting in improvements in the cerebral metabolic
state, results in further deterioration despite recovery of
intracellular pH. These data may help to explain the more
frequent occurrence of DKA-related cerebral injury during
DKA treatment, rather than at the time of presentation.
Treatment with bumetanide to inhibit Na-K-2Cl cotrans-
port results in improvements in cerebral metabolic mea-
sures, suggesting a protective effect. Our data suggest the
need for further investigation of the effects of bumetanide
during DKA treatment in children.
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